Search

Decitabine

[A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. … Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.

Oteseconazole

[A247050] The use of oteseconazole is contraindicated in females of reproductive potential due to its embryo-fetal toxicity risks.[L41635] This drug was approved by the FDA on April 26, 2022. … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC).

Vanadium

Zidebactam

[L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated … producers, and against non-enzymatic resistance mechanisms such as efflux and porin loss.

Bemiparin

These heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting … Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH).

Zuranolone

[A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression. … binding to a non-benzodiazepine site on the receptor.

PI-0824

Currently, most doctors who treat patients with PV will prescribe high-dose steroids and drugs that suppress the immune system in an effort to decrease the production of these antibodies. … The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system.

Rimegepant

[A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and

Oxybutynin

[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990] … Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.

Silodosin

[A231159] Silodosin works by binding to α_1A-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction … [A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada.